PCLOF (PharmaCielo) Moat Score: 3/10 (As of Jun. 24, 2026)


What is PharmaCielo Moat Score?

PharmaCielo PCLOF -4.35% Moat Score is 3 as of Jun. 24, 2026. The stock has 5 warning signs investors should review. Among 1,033 Drug Manufacturers companies, PharmaCielo ranks better than 86.16% on this metric.

PharmaCielo has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

PharmaCielo has No Moat: PharmaCielo operates in a competitive industry with limited market share and lacks significant intellectual property or regulatory advantages. Its cost advantages and brand strength are not sufficient to establish a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PharmaCielo might have No Moat - Very weak/transient advantages.

PharmaCielo  (OTCPK:PCLOF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PharmaCielo Moat Score Related Terms

PCLOF vs ZTS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCielo Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Moat Score distribution charts can be found below:

* The bar in red indicates where PharmaCielo's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
PharmaCielo (PCLOF) has a Moat Score of 3 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PharmaCielo ranks #143 out of 1033 companies in the Drug Manufacturers industry, placing it in the top 13.8%.
Is PharmaCielo's Moat Score too high?
PharmaCielo's current Moat Score is 3. Based on the distribution chart, PharmaCielo ranks #143 out of 1033 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does PharmaCielo's Moat Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #143 out of 1033 companies for Moat Score. This places PharmaCielo in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. PharmaCielo's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.05 — trading 48.5% below its estimated fair value. The current Moat Score is 3. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Moat Score is 3 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.